Rapamycin enriches for CD4+ CD25+ CD27+ Foxp3+ regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis

Cytotherapy

Volumn 9, Issue 2, 2007, Pages 144-157

  Keever Taylor, C A ^a   Browning, M B ^a   Johnson, B D ^a   Truitt, R L ^a   Bredeson, C N ^a   Behn, B ^a   Tsao, A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CELL PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CD4+ CD25+ CD27+ FOXP3+ REGULATORY T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CELL SELECTION; CONTROLLED STUDY; CULTURE MEDIUM; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD27; ANTIGENS, CD4; ANTIGENS, CD45; CELL PROLIFERATION; CELLS, CULTURED; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; SIROLIMUS; T-LYMPHOCYTES, REGULATORY;

EID: 34047130792     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240601145223     Document Type: Article

References (50)

1. Sakaguchi, S., Fukuma, K. and Kuribayashi, K. (1985) Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med, 161, pp. 72-87.
2. Sakaguchi, S., Sakaguchi, N. and Asano, M. (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol, 155, pp. 1151-1164.
3. Hori, S., Nomura, T. and Sakaguchi, S. (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science, 299, pp. 1057-1061.
4. Dieckmann, D., Plottner, H. and Berchtold, S. (2001) Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med, 193, pp. 1303-1310.
5. Jonuleit, H., Schmitt, E. and Stassen, M. (2001) Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med, 193, pp. 1285-1294.
6. +T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med, 193, pp. 1295-1302.
7. + immunoregulatory T-cells of donor origin suppress alloreactivity after BMT. Biol Blood Marrow Transplant, 8, pp. 525-535.
8. + regulatory T cells. Nat Immunol, 4, pp. 330-336.
9. +T regulatory cells. Nat Immunol, 4, pp. 337-342.
10. Gambineri, E., Torgerson, TR and Ochs, HD. (2003) Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol, 15, pp. 430-435.
11. Wang, HY, Matsui, M. and Saida, T. (2002) Immunological disturbances in the central nervous system linked to MRI findings in multiple sclerosis. J Neuroimmunol, 125, pp. 149-154.
12. highT regulatory cells and their IL-10 production in multiple sclerosis. J Neuroimmunol, 144, pp. 125-131.
13. + regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med, 199, pp. 1285-1291.
14. + regulatory T cells in patients with multiple sclerosis. J Exp Med, 199, pp. 971-979.
15. +T cells in the thymus of patients with autoimmune myasthenia gravis. Blood, 105, pp. 735-741.
16. Asseman, C., Fowler, S. and Powrie, F. (2000) Control of experimental inflammatory bowel disease by regulatory T cells. Am J Respir Crit Care Med, 162, p. S185.
17. Suri-Payer, E. and Cantor, H. (2001) Differential cytokine requirements for regulation of autoimmune gastritis and colitis by CD4(+)CD25(+) T cells. J Autoimmun, 16, pp. 115-123.
18. + regulatory T cells. J Immunol, 170, pp. 3939-3943.
19. +T cells controlling distinct organ-specific autoimmune diseases. Proc Natl Acad Sci USA, 100, pp. 15806-15811.
20. Tang, Q. and Henriksen, KJ (2004) In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med, 199, pp. 1455-1465.
21. + regulatory T cells control induction of autoimmune hemolytic anemia. Blood, 105, pp. 3746-3748.
22. + regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol, 169, pp. 4712-4716.
23. + immunoregulatory T cells that control autoimmune diabetes. Immunity, 12, pp. 431-440.
24. Godfrey, WR, Ge, YG and Spoden, DJ (2004) In vitro-expanded human CD4(+) CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood, 104, pp. 453-461.
25. high regulatory T cells. Blood, 104, pp. 895-903.
26. +-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood, 105, pp. 750-758.
27. + regulatory T cells suppress effector T cell proliferation. Clin Immunol, 115, pp. 3-9.
28. Abraham, RT and Wiederrecht, GJ. (1996) Immunopharmacology of rapamycin. Annu Rev Immunol, 14, pp. 483-510.
29. Sehgal, SN. (2003) Sirolimus: Its discovery, biological properties, and mechanism of action. Transplant Proc, 35, pp. 7S-14S.
30. Terada, N., Lucas, JJ and Szepesi, A. (1993) Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J Cell Physiol, 154, pp. 7-15.
31. + T cells in the periphery. Transplantation, 77, pp. 183-189.
32. Baan, CC, van der Mast, BJ and Klepper, M. (2005) Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation, 80, pp. 110-117.
33. Game, DS, Hernandez-Fuentes, MP and Lechler, RI. (2005) Everolimus and basiliximab permit suppression by human CD4CD25 cells in vitro. Am J Transplant, 5, pp. 454-464.
34. Shibutani, S., Inoue, F. and Aramaki, O. (2005) Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. Transplantation, 79, pp. 904-913.
35. + regulatory T cells. Blood, 107, pp. 1018-1023.
36. + regulatory T cells. Blood, 105, pp. 4743-4748.
37. Koenen, HJPM, Fasse, E. and Joosten, I. (2005) CD27/CFSE-based ex vivo selection of highly suppressive alloantigen-specific human regulatory T cells. J Immunol, 174, pp. 7573-7583.
38. + regulatory T cells in inflamed synovia. J Exp Med, 201, pp. 1793-1803.
39. Ramadan, G., Konings, S. and Kurup, VP (2004) Generation of aspergillus- and CMV- specific T-cell responses using autologous fast DC. Cytotherapy, 6, pp. 223-234.
40. + T regulatory cells. J Immunol, 176, pp. 3301-3305.
41. - T cells. J Clin Invest, 112, pp. 1437-1443.
42. - cells. Proc Natl Acad Sci USA, 102, pp. 4103-4108.
43. + T regulatory cells in humans. Hum Immunol, 66, pp. 13-20.
44. Gavin, MA, Torgerson, TR and Houston, E. (2006) Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA, 103, pp. 6659-6664.
45. + tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol, 16, pp. 1055-1068.
46. + regulatory T cells at the single-cell level. Eur J Immunol, 35, pp. 1681-1691.
47. Terada, N., Franklin, RA and Lucas, JJ (1993) Failure of rapamycin to block proliferation once resting cells have entered the cell cycle despite inactivation of p70 S6 kinase. J Biol Chem, 268, pp. 12062-12068.
48. + Tregs. J Clin Invest, 115, pp. 2904-2913.
49. + T cells with a regulatory phenotype and function. Eur J Immunol, 35, pp. 2896-2908.
50. Sospedra, M. and Martin, R. (2005) Immunology of multiple sclerosis. Annu Rev Immunol, 23, pp. 683-747.